학술논문
High rate of durable responses with undetectable minimal residual disease with front-line venetoclax and rituximab in young, fit patients with chronic lymphocytic leukemia and an adverse biological profile: results of the GIMEMA phase II LLC1518 – VERITAS study
Document Type
Article
Author
Mauro, F.R.; Starza, I.D.; Molinari, M.C.; De Novi, L.A.; De Propris, M.S.; Nanni, M.; Giudice, I.D.; Guarini, A.; Foà, R.; Messina, M.; Arena, V.; Fazi, P.; Vignetti, M.; Piciocchi, A.; Reda, G.; Mattiello, V.; Neri, A.; Trentin, L.; Visentin, A.; Coscia, M.; Vitale, C.; Sportoletti, P.; Orsucci, L.; Casaluci, G.M.; Marasca, R.; Murru, R.; Laurenti, L.; Ilariucci, F.; Stelitano, C.; Mannina, D.; Massaia, M.; Rigolin, G.M.; Cuneo, A.; Scarfò, L.; Marchetti, M.; Pietrasanta, D.; Levato, L.; Tani, M.; Arcari, A.; Musuraca, G.; Deodato, M.; Galieni, P.; Patrizi, V.B.; Gottardi, D.; Liberati, A.M.; Giordano, A.; Albano, F.
Source
In: Haematologica . (Haematologica, August 2023, 108(8):2091-2100)
Subject
Language
English
ISSN
15928721
03906078
03906078